AngioDynamics (ANGO) Misses Q1 EPS by 2c, Revenues Beat; Offers FY19 Revenue Outlook Above Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
AngioDynamics Reports Fiscal 2019 First Quarter Financial Results
September 27, 2018 7:00 AM EDTFiscal 2019 First Quarter Highlights
Net sales of $85.3 million, flat versus prior year Gross margin expanded 380 basis points year over year to 52.1% GAAP EPS of $(0.01) per share; adjusted EPS of $0.16 per share Cash used in operations of $8.9 million; capital expenditures of $0.7 million Announced two acquisitions as part of the Companys strategic focus on building a continuum of care within the oncology space; BioSentry Tract Sealant System technology from Surgical Specialties, LLC... More